Omega Diagnostics signs testing deal with DAM Health
As well as Covid-19 tests, the agreement can also be broadened to other areas.
Omega Diagnostics has agreed an exclusive partnership with DAM Health to provide its Covid-19 lateral flow tests (LFTs).
Omega has already received an initial purchase order in excess of £750,000 to supply its Visitect Covid-19 antigen LFT to DAM’s clinics throughout the UK and Europe.
The deal is for an initial period of 12 months, which gives DAM the permission to exclusively use, sell and promote the test throughout its network of more than 100 clinics in the UK and Europe.
It is currently using approximately 200,000 in-clinic Covid tests per month. A recent study by FIND Diagnostics showed that Omega’s LFT delivered results of 100% in specificity and 96.4% in sensitivity.
There is also the possibility for Omega to broaden the partnership to include its antigen self-test LFT – once approved – and for DAM Health to sell its Food Detective product throughout its network.
Colin King, chief executive at Omega Diagnostics, said: “We have been actively seeking commercial partners for our Covid-19 antigen tests with the support of Lansdown Strategic Capital.